An overview of investigational and experimental drug treatment strategies for Marfan syndrome.

Violette Deleeuw, Adelbert De Clercq, Julie De Backer, Patrick Sips

Onderzoeksoutput: Bijdrage aan tijdschriftA2: Artikel in een internationaal wetenschappelijk tijdschrift met peer review, dat niet inbegrepen is in A1peer review

Uittreksel

Marfan syndrome (MFS) is a heritable connective tissue disorder caused by pathogenic variants in the gene coding for the extracellular matrix protein fibrillin-1. While the disease affects multiple organ systems, the most life-threatening manifestations are aortic aneurysms leading to dissection and rupture. Other cardiovascular complications, including mitral valve prolapse, primary cardiomyopathy, and arrhythmia, also occur more frequently in patients with MFS. The standard medical care relies on cardiovascular imaging at regular intervals, along with pharmacological treatment with β-adrenergic receptor blockers aimed at reducing the aortic growth rate. When aortic dilatation reaches a threshold associated with increased risk of dissection, prophylactic surgical aortic replacement is performed. Although current clinical management has significantly improved the life expectancy of patients with MFS, no cure is available and fatal complications still occur, underscoring the need for new treatment options. In recent years, preclinical studies have identified a number of potentially promising therapeutic targets. Nevertheless, the translation of these results into clinical practice has remained challenging. In this review, we present an overview of the currently available knowledge regarding the underlying pathophysiological processes associated with MFS cardiovascular pathology. We then summarize the treatment options that have been developed based on this knowledge and are currently in different stages of preclinical or clinical development, provide a critical review of the limitations of current studies and highlight potential opportunities for future research.
Oorspronkelijke taalEngels
TijdschriftJournal of Experimental Pharmacology
Volume13
Pagina's (van-tot)755-779
Aantal pagina’s24
ISSN1179-1454
DOI's
PublicatiestatusGepubliceerd - 11-aug.-2021
Extern gepubliceerdJa

Vingerafdruk

Bekijk de onderzoeksthema's van 'An overview of investigational and experimental drug treatment strategies for Marfan syndrome.'. Samen vormen ze een unieke vingerafdruk.

Dit citeren